About Metabolic Dysfunction-Associated Steatohepatitis (MASH) MASH is a chronic, progressive metabolic disease affecting the liver, which can be potentially life-threatening if not properly managed
This paper gives a fine overview of the current status and potentials ahead in development of peptide pharmaceuticals
Safe disposal protects both the user and others
By activating GLP-1 receptors, semaglutide slows the rate at which food leaves the stomach (delayed gastric emptying), enhances insulin secretion when blood glucose is elevated, and acts on appetite centres in the brain to promote satiety
Poster presented at: 59th Annual Meeting of the European Association for the Study of Diabetes , October 2-6, 2023, Hamburg, Germany.
Not recommended for children, adolescents, pregnant and lactating women